Last reviewed · How we verify
Flucortolone (FLUOCORTOLONE)
Flucortolone (generic name: FLUOCORTOLONE) is a fluocortolone drug. It is currently in Phase 2 development.
Flucortolone works by binding to glucocorticoid receptors in the body, which helps to reduce inflammation and suppress the immune system.
Flucortolone is a small molecule corticosteroid drug of the fluocortolone class. Its mechanism of action involves binding to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects. However, due to limited information, its target and approved indications are unknown. The commercial status of flucortolone is also unclear, with no information available on its patent status or generic manufacturers. Further research is needed to fully understand its clinical applications and safety profile.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FLUOCORTOLONE |
|---|---|
| Drug class | fluocortolone |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's immune system as a fire alarm that sounds when it detects something foreign. Flucortolone helps to turn down the volume on the fire alarm, reducing the inflammation and immune response that can cause harm. This allows the body to heal and recover from injuries or infections.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Flucortolone CI brief — competitive landscape report
- Flucortolone updates RSS · CI watch RSS
Frequently asked questions about Flucortolone
What is Flucortolone?
How does Flucortolone work?
What is the generic name of Flucortolone?
What drug class is Flucortolone in?
What development phase is Flucortolone in?
Related
- Drug class: All fluocortolone drugs
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing